BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 19, 2004
View Archived Issues
Celltech Agrees To Buyout By UCB For $2.7B In Cash
LONDON - Celltech Group plc, the UK's largest biotechnology company, has agreed to be taken over by UCB SA, of Brussels, Belgium, in an all-cash deal that values Celltech at about £1.5 billion (US$2.7 billion). (BioWorld Today)
Read More
Chiron's Failed Sepsis Drug Taking On CAP In Phase III
Read More
FDA: Critical Path Initiative' Sharpens Drug Development
Read More
Pozen Starts Phase III Migraine Program, Hits $15M Milestone
Read More
Neose Offering Brings In $34M For EPO, G-CSF Development
Read More
Panacos Attracts $18.3M Round To Fund HIV Drug Development
Read More
Other News To Note
Read More